Charles-River-WIL-Research-acquisition
Earlier this year, Charles River told us it was expecting 2016 to be a “robust year” - now, it is closing out the year with several finalized acquisitions and a newly announced CRISPR license.
The company started the year by announcing its intent to acquire WIL Research for approximately $585m in cash. The acquisition was finalized in April.
In June, Charles River acquired Blue Stream Laboratories, expanding the company’s biologic and biosimilar development capabilities.
Continuing its CRO buy up in September, the company purchased Agilux Labs for $64m, adding integrated discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic (DMPK) services, and pharmacology services.